Uncategorized
2018 MSK Cardio-Oncology Symposium
Admin • CCON • 3/8/2018
2018 MSK Cardio-Oncology Symposium: Cardiovascular Health and Disease During and After Cancer Therapy – A Case Based Curriculum Date & Location Friday, May 18, 2018 7:00 AM – Saturday,... Read more »
BBC Radio 4: Hearts and Cancer
Admin • CCON • 9/20/2017
September 20, 2017 | BBC Radio 4: Inside Health Hearts and Cancer As London hosts the first ever Cardio-Oncology Summit in Europe, specialists from both fields discuss how to treat... Read more »
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter
Admin • CCON • 2/2/2016
Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article
Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies
Admin • CCON • 12/16/2015
REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent... Read more »
Mixed Results for Herceptin Cardiotoxicity Prevention
Admin • CCON • 12/10/2015
Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »
Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer
Admin • CCON • 12/9/2015
SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »
Can cancer itself damage the heart?
Admin • CCON • 12/3/2015
Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »
Harwich Port woman blindsided by chemotherapy
Admin • CCON • 11/29/2015
Breast cancer was a devastating diagnosis for Kathleen Mingle, a teacher who played tennis, ran and generally led an active and fit life. But the shock was compounded when she... Read more »
CCC 2015: Improving Cardiac Care for Cancer Patients
Admin • CCON • 11/19/2015
CCS Position Statement Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society’s (CCS) first position statement on cardiovascular complications... Read more »
NIH Funding Opportunity: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)
Admin • CCON • 11/17/2015
This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to... Read more »